These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 33065367)

  • 41. Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis.
    Tsurikisawa N; Oshikata C; Watanabe M; Tsuburai T; Kaneko T; Saito H
    Clin Exp Allergy; 2018 Oct; 48(10):1305-1316. PubMed ID: 29908086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polyangiitis overlap syndrome of granulomatosis with polyangiitis (Wegener's granulomatosis) and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
    Uematsu H; Takata S; Sueishi K; Inoue H
    BMJ Case Rep; 2014 Feb; 2014():. PubMed ID: 24577169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis.
    Padoan R; Chieco Bianchi F; Marchi MR; Cazzador D; Felicetti M; Emanuelli E; Vianello A; Nicolai P; Doria A; Schiavon F
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3225-3227.e2. PubMed ID: 32505716
    [No Abstract]   [Full Text] [Related]  

  • 44. Eosinophilic Granulomatosis with Polyangiitis Presenting with Central Retinal Artery Occlusion During Treatment with Anti-interleukin-5 Receptor Monoclonal Antibody.
    Nishiyama H; Tajiri T; Yamabe T; Yasukawa T; Takeda N; Fukumitsu K; Fukuda S; Kanemitsu Y; Uemura T; Ohkubo H; Takemura M; Maeno K; Ito Y; Oguri T; Naniwa T; Niimi A
    Intern Med; 2021 Nov; 60(22):3631-3634. PubMed ID: 34092731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis.
    Vultaggio A; Nencini F; Bormioli S; Vivarelli E; Dies L; Rossi O; Parronchi P; Maggi E; Matucci A
    Allergy Asthma Immunol Res; 2020 Sep; 12(5):885-893. PubMed ID: 32638567
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
    Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
    Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
    Portacci A; Campisi R; Buonamico E; Nolasco S; Pelaia C; Crimi N; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Scichilone N; Pelaia G; Crimi C; Carpagnano GE
    ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37908397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab.
    Hočevar A; Kopač P; Rotar Ž; Novljan MP; Škrgat S
    J Allergy Clin Immunol Pract; 2020; 8(7):2448-2449. PubMed ID: 32304835
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
    Doubelt I; Pulenzas N; Carette S; Pagnoux C;
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients.
    Jachiet M; Samson M; Cottin V; Kahn JE; Le Guenno G; Bonniaud P; Devilliers H; Bouillet L; Gondouin A; Makhlouf F; Meaux-Ruault N; Gil H; Bienvenu B; Coste A; Groh M; Giraud V; Dominique S; Godeau B; Puéchal X; Khouatra C; Ruivard M; Le Jeunne C; Mouthon L; Guillevin L; Terrier B;
    Arthritis Rheumatol; 2016 Sep; 68(9):2274-82. PubMed ID: 26946346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.
    Groh M; Pagnoux C; Baldini C; Bel E; Bottero P; Cottin V; Dalhoff K; Dunogué B; Gross W; Holle J; Humbert M; Jayne D; Jennette JC; Lazor R; Mahr A; Merkel PA; Mouthon L; Sinico RA; Specks U; Vaglio A; Wechsler ME; Cordier JF; Guillevin L
    Eur J Intern Med; 2015 Sep; 26(7):545-53. PubMed ID: 25971154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis.
    Higashitani K; Yoshimi R; Sato Y; Watanabe T; Ihata A
    Mod Rheumatol Case Rep; 2022 Jan; 6(1):87-92. PubMed ID: 34473835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Severe cardiomyopathy revealing antineutrophil cytoplasmic antibodies-negative eosinophilic granulomatosis with polyangiitis.
    Bouiller K; Samson M; Eicher JC; Audia S; Berthier S; Leguy V; Humbert O; Martin L; Lorgis L; Cottin Y; Bonnotte B; Lorcerie B
    Intern Med J; 2014 Sep; 44(9):928-31. PubMed ID: 25201426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience.
    Özdel Öztürk B; Yavuz Z; Aydın Ö; Mungan D; Sin BA; Demirel YS; Bavbek S
    Int Arch Allergy Immunol; 2022; 183(12):1281-1290. PubMed ID: 36126640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
    Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
    Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Onset of eosinophilic granulomatosis with polyangiitis (EGPA) after anti-Th2 biotherapy initiation in severe asthma patients: Report of 3 cases.
    Fargeas M; Devouassoux G; Gerfaud-Valentin M
    Respir Med Res; 2024 Jun; 85():101070. PubMed ID: 38141578
    [No Abstract]   [Full Text] [Related]  

  • 57. Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.
    Menzella F; Galeone C; Ghidoni G; Ruggiero P; Capobelli S; Simonazzi A; Catellani C; Scelfo C; Livrieri F; Facciolongo N
    Multidiscip Respir Med; 2021 Jan; 16(1):779. PubMed ID: 34221399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of Eosinophilic Granulomatosis With Polyangiitis and Associated Health Care Utilization Among Patients With Concomitant Asthma in US Commercial Claims Database.
    Gokhale M; Bell CF; Doyle S; Fairburn-Beech J; Steinfeld J; Van Dyke MK
    J Clin Rheumatol; 2021 Apr; 27(3):107-113. PubMed ID: 31693654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
    Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
    Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
    Pouliquen IJ; Austin D; Steinfeld J; Yancey SW
    Clin Ther; 2021 Jul; 43(7):1278-1280. PubMed ID: 34187697
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.